OBJECTIVE: To comprehensively evaluate the safety

efficacy and economy of Shexiang Baoxin pills and compound Danshen dropping pills in the treatment of angina pectoris of coronary heart disease based on evidencebased evidence. METHODS: Review Manager 5. 2 software was used for Meta-analysis after retrieving published literature at home and abroad

screening literature and conducting quality evaluation. The efficacy and safety of Shexiang Baoxin pills（ study group） and compound Danshen dropping pills（ control group） in the treatment of angina pectoris of coronary heart disease were evaluated

and based on the results

the pharmacoeconomics was evaluated.RESULTS: A total of 9 literature were included

with 779 patients. Meta-analysis results showed that the effective rates of symptom improvement in the study group and the control group were respectively 90. 41% and 72. 57%

with statistically significant differences（ RR = 1. 37

95% CI = 1. 24-1. 51

P < 0. 000 01）. The effective rate of ECG improvement in the study group and the control group were respectively 79. 41% and 61. 45%

and the difference was statistically significant（ RR = 1. 45

95% CI = 1. 28-1. 64

P < 0. 000 01）. The incidence of adverse drug reactions in the study group was 7. 96%

lower than the 13. 27% in the control group

the difference was not statistically significant（ RR = 0. 61

95% CI = 0. 35-1. 05

P = 0. 07）. The cost-effectiveness ratios of the treatment regimens in the study group and the control group were respectively 507. 99 and 579. 66

and the incremental cost-effectiveness ratio was 216. 42. The sensitivity analysis showed that the cost-effectiveness analysis results were stable. CONCLUSIONS:The efficacy of Shexiang Baoxin pills in improving symptoms and electrocardiogram of patients with angina pectoris of coronary heart disease is better than that of compound Danshen dropping pills

the safety is comparable to that of compound Danshen dropping pills

but the drug cost is higher than that of compound Danshen dropping pills. For every additional effect

patients who use Shexiang Baoxin pills will spend 216. 42 yuan. In the clinical treatment of angina pectoris of coronary heart disease

the treatment regimen can be selected according to the patients’ willingness to pay. If the willingness to pay is higher than the incremental cost-effectiveness ratio

Shexiang Baoxin pills are the dominant scheme. Otherwise

compound Danshen dropping pills are the dominant solution.